TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00104702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02975960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of autologous stromal vascular fraction
Description: 1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously.
Study: NCT01668004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: GLM 50 mg subcutaneously once monthly.
Study: NCT00444314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem® NCD
Description: NCD suspension, 1500 mg TID daily for 6 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem® NCD
Description: NCD suspension, 1500 mg TID daily for 6 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
Study: NCT00601341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbosacral joint manipulation
Description: lumbosacral joint manipulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar passive range of motion
Description: lumbar passive range of motion

Intervention type: OTHER
Group type: OTHER
Intervention: No active intervention
Description: Lie on exam table for 3 minutes
Study: NCT01997164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study: NCT03768037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Pemetrexed
Description: Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Study: NCT01137890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Eight capsules administered daily in split doses at 22:00 and 09:00.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules administered in split doses at 22:00 and 09:00.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine Hydrochloride
Description: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine Hydrochloride
Description: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neurocognitive and Performance Battery
Description: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive and Performance Battery
Description: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Assessments
Description: Participants answer questions about smoking and smoking behaviors are monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Assessments
Description: Participants answer questions about smoking and smoking behaviors are monitored.
Study: NCT02169648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
Study: NCT01752218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arcuate incision
Study: NCT04193852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Description: Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product
Description: Coated Tablets
Study: NCT01925638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study: NCT04449783

Intervention type: OTHER
Intervention: pre-operative screening
Description: reported symptoms plus nose and throat swabbing 48 hrs prior to surgery

Intervention type: OTHER
Intervention: telephone consult
Description: telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
Study: NCT03712332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Group
Description: The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
Study: NCT03598569

Intervention type: OTHER
Intervention: dyspnea
Description: dyspnea assessment

Intervention type: OTHER
Intervention: dyspnea
Description: dyspnea assessment
Study: NCT01984879

Intervention type: OTHER
Intervention: Survey with structured questionnaire form for inflammatory bowel disease patient group
Description: For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
Study: NCT00861861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: comparison of two drugs in increasing HDL-C and adiponectin
Study: NCT03297658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electro-acupuncture (EA)
Description: stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Micro electrodes will be placed but there will be no stimulation
Study: NCT04233021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg/d
Study: NCT03290352

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
Study: NCT01426802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: Drug 50mg vildagliptin bid
Study: NCT00861861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: comparison of two drugs in increasing HDL-C and adiponectin
Study: NCT03929692

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-layer health promotion program

Intervention type: OTHER
Group type: OTHER
Intervention: Standard health education

Intervention type: OTHER
Group type: OTHER
Intervention: Standard health education
Study: NCT01088685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Blister Patch
Description: Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Pflaster
Description: Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
Study: NCT02840890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic technique
Description: Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
Study: NCT02487511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of HP therapy
Description: the comparison of HP eradication rate between 7 days and 14 days
Study: NCT01575574

Intervention type: DRUG
Group type: OTHER
Intervention: GADOXETIC ACID
Description: all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
Study: NCT05165706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Mediterranean Low Carbohydrate Diet
Description: Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Standard Low Carbohydrate Diet
Description: Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Standard Low Fat Diet
Description: Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
Study: NCT04516278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection
Study: NCT04106245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in PACK Health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT02840890

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
Study: NCT01592669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: bilateral PLR was achieved by raising the legs of patient
Study: NCT02683226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vipdomet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incresync
Study: NCT04224285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dayzz app
Description: Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
Study: NCT01911000

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT and hyperthermia after TACE
Study: NCT03097224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Four weeks of tele-supervised prehabilitation
Study: NCT02007629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
Study: NCT00765414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 30 mg/kg qow f and 40 mg/kg qow
Study: NCT03121521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Description: melatonin 10mg daily p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10mg daily p.o.
Study: NCT03085680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
Study: NCT00487084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine-CP-saline (MCS)
Description: 3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline-2CP-morphine (SCM)
Description: 6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline-lidocaine-morphine (SLM)
Description: 3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
Study: NCT02822404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urinary and blood sample for Cystatine dosage
Description: Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
Study: NCT01184716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D fortification
Description: Bread and milk fortified with vitamin D3
Study: NCT02634931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12G gel
Description: NPC-12G gel is administered topically twice a day for 52 weeks or longer
Study: NCT02670460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIVE Catheter
Description: Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
Study: NCT00438399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C. propionate - Corticosteroid 1
Description: Twice daily application
Study: NCT02261961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDAP
Description: Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
Study: NCT00438399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C. propionate- Corticosteroid 2
Description: Twice daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C. propionate -Corticosteroid 3
Description: Twice daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid 1- C. propionate
Description: Twice daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid 2 - C. propionate
Description: Twice daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid 3 - C. propionate
Description: Twice daily application
Study: NCT02261961

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TDAP
Description: Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute Resistance Exercise
Description: Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise Training
Description: Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training Follow-up
Description: Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post-training Follow-up
Description: Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement (Muscle Armor)
Description: Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Kool-Aid)
Description: Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
Study: NCT04436393

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360 test
Description: tumor cfDNA testing
Study: NCT01195454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous
Study: NCT02196753

Intervention type: OTHER
Intervention: PET CT
Description: All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background.

Intervention type: OTHER
Intervention: PET CT
Description: All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background.
Study: NCT00734552

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: α-Keto Acid with low protein diet
Description: Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normal protein diet
Description: Diet contain protein 1.0-1.2 g/kg/d.
Study: NCT02523950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged phacoemulsification and DMEK
Description: Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients.
Study: NCT06007118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI
Description: accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
Study: NCT02523950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined phacoemulsification and DMEK
Description: Routine phacoemulsification and DMEK are performed simultaneously.